International Journal of Risk & Safety in Medicine 22 (2010) 89-92.

 

Peter R. Breggin

 

Abstract: Electroconvulsive therapy (ECT) and the machines that deliver it have never been tested for safety and efficacy in order to receive approval from the FDA. The American Psychiatric Association and ECT advocates protested when the FDA took steps to classify the machines as posing “an unreasonable risk of illness or injury”, which would have required their testing before approval. Without requiring this testing, the FDA is now preparing to classify the treatment and the machines as safe. This article reviews evidence demonstrating that ECT is very harmful to the brain and mind, and concludes that the FDA should demand the usual testing, starting with animals, that is required before psychiatric treatments and machines are approved for marketing and use.

"A dangerous assignment," In Howard Rosenthal (Ed.). Favorite Counseling and Therapy Homework Assignments: Leading Therapists Share their Most Creative Strategies, pp. 58-59. Philadelphia: Brunner Routledge, 2001.

"Electroshock: Scientific, Ethical, and Political Issues." International Journal of Risk & Safety In Medicine, 11:5-40, 1998.

Breggin, P.R. (1992). A Case of Fluoxetine-induced Stimulant Side Effects with Suicidal Ideation Associated with a Possible Withdrawal Syndrome ("Crashing").  International Journal of Risk & Safety in Medicine, 3, 325-328.

Risks and Mechanism of Action of Stimulants. NIH Consensus Development Conference on Diagnosis and Treatment of Attention Deficit Hyperactivity Disorder, November 16-18, 1998.